For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or the antigen attached or conjugated to a protein.
Scope of the Report:
This report focuses on the Conjugate Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
This protein has a key role in enhancing the immunogenic property of the polysaccharide. These vaccines are mainly used to immunize infants and children against invasive disease caused by Hib bacteria, H. influenzae, Streptococcus pneumoniae, and Neisseria meningitidis.
The increase in use of conjugate vaccines for adults, rise in number of regulatory approvals for conjugate vaccines, growth in prevalence of diseases caused by microorganisms such as Streptococcus pneumoniae and Neisseria meningitidis, and technological advancements majorly drive the growth of the market. In contrast, low accessibility to vaccines in remote areas and complex production procedure of conjugate vaccine restraint the market growth.
The worldwide market for Conjugate Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Neuron Biotech
- Serum Institute of India
- Sanofi Pasteur
- Bharat Biotech
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccines
Market Segment by Applications, can be divided into
There are 15 Chapters to deeply display the global Conjugate Vaccines market.
Chapter 1, to describe Conjugate Vaccines Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Conjugate Vaccines, with sales, revenue, and price of Conjugate Vaccines, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Conjugate Vaccines, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Conjugate Vaccines market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Conjugate Vaccines sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source